Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.365 -4.64% -4.86% 470K
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
Published: 2021-11-23 (Crawled : 13:30) - biospace.com/
APVO 3 d | $0.76 6.67% 6.25% 220K
|
Health Technology
|
| O: 25.38%
H: 132.18%
C: 79.07%
treatment myeloid leukemia phase 1 expansion phase 1b leukemia trial therapeutics apvo436 acute myeloid leukemia phase 2b
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Published: 2021-03-08 (Crawled : 12:00) - biospace.com/
GLSI | $13.12 0.54% 0.53% 42K
|
Health Technology
|
| O: 0.04%
H: 130.25%
C: 61.67%
cancer breast cancer trial
BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
Published: 2020-12-14 (Crawled : 13:05) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: 10.28%
H: 123.47%
C: 44.05%
heart phase 3 trial cardiamp
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Published: 2023-07-05 (Crawled : 14:00) - globenewswire.com
ALLR | $1.53 2.0% 1.96% 760K
|
n/a
|
| O: -1.59%
H: 117.58%
C: 33.55%
ixempra breast indicate cancer trial potential
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 9.01%
H: 116.14%
C: 69.12%
solid tumors ongoing phase 1 trial phase 3 phase 2
Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®
Published: 2023-06-05 (Crawled : 13:00) - biospace.com/
ENDPQ | $0.0006 -50.0% 620K
|
n/a
|
| O: -6.67%
H: 114.29%
C: 107.14%
xiaflex publication
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
KRBP | $2.3 -90.21% 15K
|
Health Technology
|
| O: -3.52%
H: 111.44%
C: 40.92%
cancer biopharma trial agreement
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $11.9 3.48% 3.36% 47K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K
|
|
| O: 20.13%
H: 108.9%
C: 46.07%
research respiratory trial results publication
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.5 -1.33% -1.35% 370K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.12%
H: 0.1%
C: -1.6%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.78%
H: 0.45%
C: -1.66%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -7.13%
H: 96.21%
C: 15.59%
covid ev biotech trial
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
Published: 2023-07-27 (Crawled : 15:20) - biospace.com/
URGN | $14.32 0.56% 0.56% 320K
|
Health Technology
|
| O: 3.44%
H: 94.21%
C: 91.95%
ugn-102 trials potential therapy
Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial
Published: 2022-09-20 (Crawled : 17:00) - biospace.com/
TSOI | $0.0007 0.0% 13M
|
Manufacturing
|
| O: 0.99%
H: 93.14%
C: 32.35%
solutions trial international
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
RVPH | $3.03 -5.31% -5.61% 120K
|
|
| O: 14.58%
H: 91.92%
C: 75.76%
phase 2 schizophrenia positive results trial trial results
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.91 0.58% 0.58% 1.1M
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.